Login to Your Account

ACR Roundup

Wednesday, November 9, 2011
• BioCryst Pharmaceuticals Inc., of Research Triangle Park, N.C., presented new Phase IIb results showing that BCX4208 in patients with gout who have failed to reach serum uric acid level (sUA) of < 6 mg/dL on allopurinol alone met the primary endpoint, defined as the proportion of patients with sUA < 6 mg/dL at day 85. The 279-patient study showed that, when added to allopurinol 300 mg, BCX4208 was superior to allopurinol plus placebo (p = 0.009).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription